Navigation Links
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Date:8/5/2009

RALEIGH, N.C., Aug. 5 /PRNewswire/ -- Cancer Centers of North Carolina, an affiliate of US Oncology, Inc., continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy allows physicians to deliver precise radiation treatment to a patient's cancerous tumor and is rapidly becoming the treatment of choice for certain types of cancer.

With HDR brachytherapy, radiation is delivered directly to the cancer target through the use of catheters, needles or applicators inserted into a body cavity or directly into the tumor. A computer-controlled delivery system is used to optimize the dose distribution to the target. As a result of this precise delivery, the surrounding healthy tissue and critical organs are preferentially spared from high doses of radiation and side effects may be reduced.

Unlike low dose rate brachytherapy treatment, HDR therapy can be delivered on an outpatient basis at Cancer Centers of North Carolina's office, which incorporates all patient needs in one central location. In addition, treatment times for HDR brachytherapy are typically 10-15 minutes in duration instead of several days that are required for low dose rate brachytherapy. Cancer Centers of North Carolina is currently administering HDR primarily on breast and gynecologic cancers.

The HDR brachytherapy program at Cancer Centers of North Carolina is directed by its board-certified radiation oncologists, Dr. John Reilly and Dr. Kolby Sidhu. "HDR brachytherapy is a very effective addition to our fight against cancer. This technique delivers a high dose of radiation directly to the area of disease," according to Dr. Reilly. Dr. Sidhu adds, "Cancer patients benefit by having more treatment options. There is also the potential benefit for a shorter course of treatment, particularly for breast cancer patients being treated with Mammosite(R)."

About Cancer Centers of North Carolina

Cancer Centers of North Carolina (CCNC) has been providing comprehensive cancer care in the greater Triangle area for 30 years. Beginning as a single physician practice, originally named Raleigh Hematology Oncology, CCNC has grown to a physician staff of thirteen medical oncologists, two radiation oncologists, a head and neck surgical oncologist and a gynecologic oncologist, and offers services in Raleigh, North Raleigh, Cary, Clayton, and Dunn. The practice provides advanced state-of-the-art diagnostic and therapeutic services including administration of chemotherapy, biologic and targeted therapies, Computed Tomography (CT), Intensity Modulated Radiation Therapy (IMRT), laboratory and pharmacy services, and an extensive clinical trials program connecting patients to leading cancer investigators around the country. CCNC brings the best of medical science and cancer care support services together in one pleasant, convenient, community- based organization. For more information, visit www.cancercentersofnc.com

CCNC is united in healing with US Oncology, supporting the nation's foremost cancer treatment and research network to accelerate the availability and use of evidence-based medicine and shared best practices. With more than 1,227 physicians treating more than 650,000 patients at 468 locations in 39 states, the US Oncology network and CCNC provide cancer patients with access to the latest advancements in therapies, clinical research and technology, as well as best-in-class clinical and operational processes that help to advance the quality, safety and cost effectiveness of cancer care. For more information, visit www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Mich. , May 31, 2016  Diplomat Pharmacy, Inc. ... pharmacy, has announced that Phil Hagerman , Chairman & ... the upcoming William Blair 36 th Annual Growth Stock ... Mr. Hagerman and Mr. Whelan are scheduled to present at ... Central Time. A live audio-only webcast of the presentation and ...
(Date:5/31/2016)... , May 31, 2016 Mundipharma ... initiation of a first-in-human clinical trial of its investigational ... - S101 is currently being developed for the treatment ... is designed to evaluate the safety and tolerability of ... several sites across the United States ...
(Date:5/31/2016)... The global biomaterials market is driven by the ... from chronic diseases. According to research report, "Global Biomaterials Market ... Forecasts (2016-2021) - (By Value; By Material Type - Polymer, ... By Region-North America, Europe , APAC, ROW; ... Italy , Japan , ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Twenty years ago it was revolutionary: enabling the people ... the voices they hear. But this approach has proven transformative, both for people who ... gained credibility and now is used around the world, but it still lags in ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... ... May 31, 2016 , ... Phynd Technologies, Inc. announced recently the signing of ... TX and Shore Medical Center – Somers Point, NJ. The new clients range in ... demonstrating the breadth of Phynd’s solution and its interoperability. , Houston Methodist is a ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
Breaking Medicine News(10 mins):